Effect of Sodium-Glucose Cotransporter-2 inhibitor in patients with type 2 daibetes mellitus

Effect of Sodium-Glucose Cotransporter-2 inhibitor in patients with type 2 daibetes mellitus - Effect of SGLT2 inhibitor in patients with type 2 daibetes mellitus

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014168

Enrollment

Registered

2014-06-04

Start date

2013-04-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

SGLT2 inhibitors for 12weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)type 2 daibetes 2)uncontrollable even after diet and excercise therapy 3)HbA1c:7.0-9.4% 4)treatment with oral hypoglycemic agents or insulin more than 12 weeks 5)age: 20-74 years 6)gender: men and women

Exclusion criteria

Exclusion criteria: 1)severe ketosis, diabetic coma 2)severe infection, before operation, severe trauma 3)allergy for the SGLT2 inhibitor 4)type 1 diabetes 5)chronic renal failure, hemodialysis 6)severe anemia 7)reject to informed consent 8)patients judged by the investigator to be ineligible for some other reason

Design outcomes

Primary

Measure	Time frame
The predictive parameters for the effect on SGLT2 inhibitor	—

Countries

Japan

Contacts

Public ContactKenta Okada

Jichi Medical University Endocrinology and Metabolism

kokada@jichi.ac.jp0285-58-7355

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026